Testing and release of drug product for distribution do not include appropriate laboratory determination of satisfactory conformance to the identity and strength of each active ingredient prior to release.
Inspection Record
Nora Apothecary and Alternative Therapies, Inc. — FDA 483 Findings
Inspectors Larry K. Austin · Marie A. FaddenThe inspectors who signed the published document.Inspector lookup
View the regulator's official source The source document is always the basis for judgement.
Findings
Written procedures are not established for the cleaning and maintenance of equipment, including utensils, used in the manufacture, processing, packing or holding of a dmg product.
Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not established and followed.
There is no written testing program designed to assess the stability characteristics ofdrug products.
Each batch of drug product requred to be free of objectionable migroorganisms is not tested through appropriate laboratory testing.
Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.
About this record
Extracted automatically from the document US FDA published on 2024-01-17. The source is available at the link above.
This is a record of that moment. Inspection findings are usually followed by the company's response and corrective action, but this page does not know how that turned out. Do not read it as the current state; check the regulator's official announcements for the latest status.
Translation and classification are automated and may differ in nuance from the source.
